• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?

IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?

September 13, 2021
Daniel Carlat, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Victoria Hendrick, MD. Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report.

Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The Eli Lilly warning followed reports of 160 adverse events, including 29 fatalities, linked to IM olanzapine/IM benzodiazepine combinations from January 2004 to September 2005 (Marder SR et al, J Clin Psychiatry 2010;71(4):433–441). Looking closely at these cases, it is unclear that this medication combination actually caused the fatalities. Many of them occurred days after the olanzapine injection (n = 12) or involved patients with serious medical illnesses or suicide attempts (n = 14), either of which may have been the actual cause of death.

In addition, subsequent controlled trials appear to show that IV and IM olanzapine are safe when combined with benzodiazepines. A double-blind, randomized controlled study that compared IV olanzapine 5 mg combined with IV midazolam 2.5–5 mg (n = 109) to IV midazolam alone (n = 115) found that the olanzapine/midazolam combination produced more rapid sedation than midazolam alone and was safe and well tolerated (Chan EW et al, Ann Emerg Med 2013;61(1):72–81). Another study of hospital patients (n = 91) who received IM olanzapine (5–10 mg) plus IM lorazepam (1–2 mg) reported no serious adverse events, even among patients who received both medications within a five-minute interval (Williams AM, Ment Health Clin 2018;8(5):208–213). Lastly, in a study that looked at 96 patients who received IM haloperidol (n = 71) or IM olanzapine (n = 25) along with a benzodiazepine, 5% of the patients in the haloperidol plus benzodiazepine group experienced hypotension, while none of the patients in the olanzapine plus benzodiazepine group had this side effect. Also, none experienced decreased oxygen saturation, except for patients who had positive alcohol breathalyzer tests or were visibly intoxicated. The authors concluded that olanzapine plus benzodiazepine is no riskier than haloperidol plus benzodiazepine, provided patients have not ingested significant amounts of alcohol (Wilson MP et al, J Emerg Med 2012;43(5):790–797).

Should we separate the administration of these meds by some time interval? The FDA does not give a clear directive on this point, unlike the European Medicines Agency, which recommends separating olanzapine and benzodiazepines by at least one hour.

The olanzapine + benzodiazepines combination is probably safe for most agitated patients who are otherwise healthy—though it is not our first choice, given the clinical controversies. This combination is best avoided in patients with compromised respiratory function (eg, COPD) or who are intoxicated with alcohol.
Hospital Psychiatry
KEYWORDS antipsychotics benzodiazepines olanzapine psychotic-agitation side-effects
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: September 13, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Agitation, CHPR, October-November-December 2021
    Note From the Editor-in-Chief
    IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?
    Can We Treat Depression by Targeting Inflammation?
    Faster Refeeding of Patients With Anorexia Nervosa Appears Safe
    Melatonin vs Memantine for ECT-Related Cognitive Impairment
    Rapid-Onset Treatment for Pedophilic Disorder
    Medications to Rapidly Treat Psychotic Agitation
    Anticholinergic Drugs and Risk of Cognitive Impairment and Dementia
    Treating Agitation in Patients with Dementia
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.